BetterLife Pharma (BETRF) Non-Current Debt (2011 - 2026)
BetterLife Pharma (BETRF) posted quarterly Non-Current Debt of $53418.8 for Q2 2026, up 47.3% year-over-year from $36265.7 in Q2 2025, and little changed quarter-over-quarter from $53536.9 in Q1 2026.
BetterLife Pharma (BETRF) Non-Current Debt (2011 - 2026) Analysis & Trends
BetterLife Pharma's Non-Current Debt history runs 12 years deep, the most recent figure standing at $53418.8 for Q2 2026.
- In Q2 2026, Non-Current Debt rose 47.3% year-over-year to $53418.8; the TTM figure through Apr 2026 stood at $53418.8 (up 47.3% YoY), while the FY2026 annual figure was $53536.9, up 51.84% from the prior year.
- Non-Current Debt for Q2 2026 stood at $53418.8, roughly flat from $53536.9 in the prior quarter.
- The five-year high for Non-Current Debt was $683037.4 in Q1 2022, with the low at $30115.8 in Q4 2022.
- The 5-year median for Non-Current Debt is $58999.5 (2023), against an average of $125489.6.
- The sharpest annual moves came in 2023 and 2025: Non-Current Debt jumped 95.91% in 2023, then tumbled 91.93% in 2025.
- BetterLife Pharma's Non-Current Debt stood at $30115.8 in 2022, then surged by 95.91% to $58999.5 in 2023, then gained by 16.84% to $68932.5 in 2024, then sank by 42.94% to $39330.2 in 2025, then surged by 35.82% to $53418.8 in 2026.
- Business Quant data shows BETRF's Non-Current Debt at $53418.8 in Q2 2026, $53536.9 in Q1 2026, and $39330.2 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 8.96 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.97 Mn |
| 10 | BetterLife Pharma | 40.15 Mn | 42.53 Mn | - | 53,418.81 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 53,418.81 |
| Jan 31, 2026 | 53,536.89 |
| Jul 31, 2025 | 39,330.25 |
| Apr 30, 2025 | 36,265.72 |
| Jan 31, 2025 | 35,257.97 |
| Oct 31, 2024 | 68,932.53 |
| Jul 31, 2024 | 65,758.02 |
| Apr 30, 2024 | 63,508.61 |
| Jan 31, 2024 | 437,079.23 |
| Oct 31, 2023 | 58,999.51 |
| Jul 31, 2023 | 59,936.30 |
| Apr 30, 2023 | 59,123.93 |
| Jan 31, 2023 | 326,339.58 |
| Oct 31, 2022 | 30,115.82 |
| Jul 31, 2022 | 31,101.09 |
| Apr 30, 2022 | 31,582.21 |
| Jan 31, 2022 | 683,037.42 |
| Oct 31, 2021 | 58,167.98 |
| Jul 31, 2021 | 58,380.49 |
| Apr 30, 2021 | 55,874.07 |